Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:05 August,2020

Why rapid antigen tests still being done in non-sealed areas, asks HC

New Delhi: Facing intense scrutiny of Delhi high court over the Covid-19 testing strategy, the AAP government on Tuesday urged it to end the monitoring, citing other PILs where the court had been satisfied by the steps taken by the government. ,But a bench of Justices Hima Kohli and Subramonium Prasad disapproved of the government’s “resistance” to the monitoring, saying the administration appeared to have got “cold feet” as it was raising “technical” grounds in a PIL. ,The court instead directed the government to explain why it was still using rapid antigen tests (RAT) in other parts of Delhi when the Indian Council of Medical Research (ICMR) advisory said it must be limited to hotspots/containment zones and healthcare settings. It ordered the government to clarify from ICMR on using RAT and RT-PCR tests across Delhi. ....read more


High Blood Pressure in COVID-19 Times

Join us today at 7:00 pm as we discuss about high blood pressure in the COVID era in Medtalks with Dr KK Aggarwal COVID edition.
Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php


CMAAO Coronavirus Facts and Myth Buster: COVID disputes

With inputs from Dr Monica Vasudev
1040: Round Table Expert Zoom Meeting on “Role of e-mediation - online dispute redressal” , 25th July, 2020, 11am-12pm,Participants: Dr KK Aggarwal, Dr AK Agarwal, Prof Mahesh Verma, Dr Ashok Gupta, ,Dr Suneela Garg, Dr JA Jayalal, Dr Jayakrishnan Alapet, Dr Anil Kumar, Mrs Upasana Arora, Dr S Sharma, Dr KK Kalra, Advocate Ira Gupta
Key points from the discussion:Litigations in the COVID era are anticipated in large numbers. The new Consumer Protection Act came into effect in July. It has a separate chapter on mediation as a dispute redressal mechanism, so that timely justice or settlement can be done at affordable cost....read more


World COVID Meter 4th August: India Number 3, 213 Countries Affected

Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17, 15M July 23, 16M July 25, 17M July 29, 18M August 1 ,Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity ,Coronavirus Cases: 18,447,759,Deaths: 697,245,Recovered: 11,680,369,ACTIVE CASES: 6,070,145 ,Currently Infected Patients 6,005,480 (99%) in Mild Condition....read more


Why do people suffer?

As per Garud Puran and Hindu mythology, one of the reasons for suffering is the debts of your past birth. Your purpose of life is to face sufferings to pay these debts. The second reason is your present deeds till today starting from birth. If your sum total of bad deeds is more than good deeds, they get added to your previous birth’s debts. ,The third reason for suffering is the form of struggle, which you entertain to attain future success. Some people do not call it as suffering. ....read more


Video of The day

Time to appeal for out of COVID 19 isolation is ninth day


Medbytes

       


Healthcare News Monitor
Sun Pharma launches Favipiravir in India at Rs 35 per tablet
India TV

Drug major Sun Pharmaceutical Industries on Tuesday said it has launched antiviral drug Favipiravir under the brand name 'FluGuard' for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India. The stocks of FluGuard will be available in the market from this week, Sun Pharma said in a regulatory filing. ,Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease, it added. ,"We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. ,This is in line with our continuous efforts to support India's pandemic response," Sun Pharma India Business CEO Kirti Ganorkar said.

Jubilant Life Sciences launches JUBI-R for COVID-19 treatment
ExpressPharma

Jubilant Life Sciences’ subsidiary, Jubilant Generics has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection). ,The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. ,A company statement informed, “Jubilant’s 24-hour helpline will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes. In order to increase the accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at the distribution of the drug.”

In the pharma industry, technology has become a mandate for some compliances
Express Pharma

The importance of information technology and its potential to enhance the life sciences industry’s performance has been accentuated by the COVID-19 crisis. Therefore, the whole value chain in the pharma sector is expected to see far-reaching changes. Bino George, Director, Solution Consulting, Infor India, explains how the Indian pharma sector can gain a competitive edge by becoming more compliant, efficient and proactive with technology-adoption and how his company can partner the pharma sector in this transformation

Another Hyderabad hospital barred from treating Covid patients
The Indian Express

Another private hospital in Hyderabad is under fire following several complaints regarding overcharging coronavirus patients. On Tuesday evening, the Telangana government issued orders prohibiting Virinchi Hospital from offering treatment to COVID-19 patients — nearly 24 hours after it took a similar action against Deccan Hospital over ‘surplus billing’. ,According to the latest orders, both hospitals are barred from admitting or treating any confirmed or suspected case of COVID-19. ,The office of the director of Public Health and Family Welfare has directed the management of Virinchi hospital to ensure treatment to patients who are currently admitted there and charge them in accordance with government’s fixed price-cap. It has also warned the hospital against cancellation of its registration if it failed to comply with government norms.